FDA Approves Xolair for Multiple Food Allergies

The medication, initially for asthma, now offers hope to individuals with food allergies by reducing the risk of severe reactions from accidental exposure.

The FDA has approved Xolair, a medication originally used for asthma, to reduce the severity of allergic reactions in individuals with multiple food allergies.
Xolair is designed for use in patients aged one year and older who are at risk of accidental exposure to food allergens, including peanuts, milk, egg, and wheat.
The medication, administered every two to four weeks by injection, has shown to enable 68% of patients to tolerate a dose of peanut protein without severe allergic symptoms.
Xolair is not approved for immediate emergency treatment of allergic reactions, such as anaphylaxis, and patients must continue to avoid foods they are allergic to.
The approval of Xolair marks a significant advancement in the management of food allergies, offering hope to millions of Americans living with this condition.